Research ExplorerPublicationsProenkephalin for the early detection of acute kidney injury...

Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease

Standard

Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease. / Breidthardt, Tobias; Jaeger, Cedric; Christ, Andreas; Klima, Theresia; Mosimann, Tamina; Twerenbold, Raphael; Boeddinghaus, Jasper; Nestelberger, Thomas; Badertscher, Patrick; Struck, Joachim; Bergmann, Andreas; Hartmann, Oliver; Kalbermatter, Stefan; Marenzi, Giancarlo; Mueller, Christian.

In: EUR J CLIN INVEST, Vol. 48, No. 10, 10.2018, p. e12999.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Breidthardt, T, Jaeger, C, Christ, A, Klima, T, Mosimann, T, Twerenbold, R, Boeddinghaus, J, Nestelberger, T, Badertscher, P, Struck, J, Bergmann, A, Hartmann, O, Kalbermatter, S, Marenzi, G & Mueller, C 2018, 'Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease', EUR J CLIN INVEST, vol. 48, no. 10, pp. e12999. https://doi.org/10.1111/eci.12999

APA

Breidthardt, T., Jaeger, C., Christ, A., Klima, T., Mosimann, T., Twerenbold, R., Boeddinghaus, J., Nestelberger, T., Badertscher, P., Struck, J., Bergmann, A., Hartmann, O., Kalbermatter, S., Marenzi, G., & Mueller, C. (2018). Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease. EUR J CLIN INVEST, 48(10), e12999. https://doi.org/10.1111/eci.12999

Vancouver

Breidthardt T, Jaeger C, Christ A, Klima T, Mosimann T, Twerenbold R et al. Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease. EUR J CLIN INVEST. 2018 Oct;48(10):e12999. https://doi.org/10.1111/eci.12999

Bibtex

@article{302553314fdf4b5cbc4deb9dea7fbafd,
title = "Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease",
abstract = "BACKGROUND: The early detection of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) is an unmet clinical need. Proenkephalin (PENK) might improve the early detection of AKI.METHODS: One hundred and eleven hospitalized CKD patients undergoing radiographic contrast procedures were enrolled. PENK was measured in a blinded fashion at baseline (before contrast media administration) and on day 1 (after contrast media administration). The potential of PENK levels to predict contrast-induced AKI was the primary endpoint.RESULTS: Baseline creatinine and baseline PENK were similar in AKI and no-AKI patients. In AKI patients, day 1 PENK (198 pmol/L vs 121 pmol/L, P < 0.01) was significantly higher compared to no-AKI patients. The area under the curve (AUC) for the prediction of AKI by day 1 PENK was 0.79, 95% CI: 0.70-0.87, similar to serum creatinine: 0.78, 95% CI: 0.61-0.95. Delta PENK was significantly higher in AKI compared to no-AKI patients (53 pmol/L vs 1 pmol/L, P < 0.01). The AUC for the prediction of AKI by delta PENK was high (0.92, 95%CI 0.82-1.00) and remained high for creatinine-blind AKI (0.94, 95% CI: 0.87-0.97).CONCLUSION: Delta PENK levels improve the early detection of contrast-induced AKI in CKD patients over serial creatinine sampling. Delta PENK accelerates the detection of creatinine-blind AKI by 24 hours.",
keywords = "Acute Kidney Injury/chemically induced, Aged, Aged, 80 and over, Area Under Curve, Biomarkers/metabolism, Contrast Media/adverse effects, Creatinine/metabolism, Early Diagnosis, Enkephalins/metabolism, Female, Hospitalization, Humans, Isotonic Solutions/administration & dosage, Male, Prospective Studies, Protein Precursors/metabolism, Renal Insufficiency, Chronic/complications, Sodium Bicarbonate/administration & dosage, Sodium Chloride/administration & dosage",
author = "Tobias Breidthardt and Cedric Jaeger and Andreas Christ and Theresia Klima and Tamina Mosimann and Raphael Twerenbold and Jasper Boeddinghaus and Thomas Nestelberger and Patrick Badertscher and Joachim Struck and Andreas Bergmann and Oliver Hartmann and Stefan Kalbermatter and Giancarlo Marenzi and Christian Mueller",
note = "{\textcopyright} 2018 Stichting European Society for Clinical Investigation Journal Foundation.",
year = "2018",
month = oct,
doi = "10.1111/eci.12999",
language = "English",
volume = "48",
pages = "e12999",
journal = "EUR J CLIN INVEST",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease

AU - Breidthardt, Tobias

AU - Jaeger, Cedric

AU - Christ, Andreas

AU - Klima, Theresia

AU - Mosimann, Tamina

AU - Twerenbold, Raphael

AU - Boeddinghaus, Jasper

AU - Nestelberger, Thomas

AU - Badertscher, Patrick

AU - Struck, Joachim

AU - Bergmann, Andreas

AU - Hartmann, Oliver

AU - Kalbermatter, Stefan

AU - Marenzi, Giancarlo

AU - Mueller, Christian

N1 - © 2018 Stichting European Society for Clinical Investigation Journal Foundation.

PY - 2018/10

Y1 - 2018/10

N2 - BACKGROUND: The early detection of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) is an unmet clinical need. Proenkephalin (PENK) might improve the early detection of AKI.METHODS: One hundred and eleven hospitalized CKD patients undergoing radiographic contrast procedures were enrolled. PENK was measured in a blinded fashion at baseline (before contrast media administration) and on day 1 (after contrast media administration). The potential of PENK levels to predict contrast-induced AKI was the primary endpoint.RESULTS: Baseline creatinine and baseline PENK were similar in AKI and no-AKI patients. In AKI patients, day 1 PENK (198 pmol/L vs 121 pmol/L, P < 0.01) was significantly higher compared to no-AKI patients. The area under the curve (AUC) for the prediction of AKI by day 1 PENK was 0.79, 95% CI: 0.70-0.87, similar to serum creatinine: 0.78, 95% CI: 0.61-0.95. Delta PENK was significantly higher in AKI compared to no-AKI patients (53 pmol/L vs 1 pmol/L, P < 0.01). The AUC for the prediction of AKI by delta PENK was high (0.92, 95%CI 0.82-1.00) and remained high for creatinine-blind AKI (0.94, 95% CI: 0.87-0.97).CONCLUSION: Delta PENK levels improve the early detection of contrast-induced AKI in CKD patients over serial creatinine sampling. Delta PENK accelerates the detection of creatinine-blind AKI by 24 hours.

AB - BACKGROUND: The early detection of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) is an unmet clinical need. Proenkephalin (PENK) might improve the early detection of AKI.METHODS: One hundred and eleven hospitalized CKD patients undergoing radiographic contrast procedures were enrolled. PENK was measured in a blinded fashion at baseline (before contrast media administration) and on day 1 (after contrast media administration). The potential of PENK levels to predict contrast-induced AKI was the primary endpoint.RESULTS: Baseline creatinine and baseline PENK were similar in AKI and no-AKI patients. In AKI patients, day 1 PENK (198 pmol/L vs 121 pmol/L, P < 0.01) was significantly higher compared to no-AKI patients. The area under the curve (AUC) for the prediction of AKI by day 1 PENK was 0.79, 95% CI: 0.70-0.87, similar to serum creatinine: 0.78, 95% CI: 0.61-0.95. Delta PENK was significantly higher in AKI compared to no-AKI patients (53 pmol/L vs 1 pmol/L, P < 0.01). The AUC for the prediction of AKI by delta PENK was high (0.92, 95%CI 0.82-1.00) and remained high for creatinine-blind AKI (0.94, 95% CI: 0.87-0.97).CONCLUSION: Delta PENK levels improve the early detection of contrast-induced AKI in CKD patients over serial creatinine sampling. Delta PENK accelerates the detection of creatinine-blind AKI by 24 hours.

KW - Acute Kidney Injury/chemically induced

KW - Aged

KW - Aged, 80 and over

KW - Area Under Curve

KW - Biomarkers/metabolism

KW - Contrast Media/adverse effects

KW - Creatinine/metabolism

KW - Early Diagnosis

KW - Enkephalins/metabolism

KW - Female

KW - Hospitalization

KW - Humans

KW - Isotonic Solutions/administration & dosage

KW - Male

KW - Prospective Studies

KW - Protein Precursors/metabolism

KW - Renal Insufficiency, Chronic/complications

KW - Sodium Bicarbonate/administration & dosage

KW - Sodium Chloride/administration & dosage

U2 - 10.1111/eci.12999

DO - 10.1111/eci.12999

M3 - SCORING: Journal article

C2 - 30009473

VL - 48

SP - e12999

JO - EUR J CLIN INVEST

JF - EUR J CLIN INVEST

SN - 0014-2972

IS - 10

ER -